A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Tumors
Latest Information Update: 31 Jul 2025
At a glance
- Drugs BL M14D1 (Primary)
- Indications Gastrointestinal cancer; Large cell carcinoma; Neuroendocrine tumours; Pancreatic cancer; Small cell lung cancer
- Focus Adverse reactions
- Sponsors SystImmune
Most Recent Events
- 31 Jul 2025 New trial record